A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial

被引：0
|
作者：
Martinez, Imanol
Kernan, Kenneth
Piasecki, Piotr
Hamilton, Joelle P.
Goh, Chee
Arkosy, Peter
Needleman, Sarah
Ratta, Raffaele
Tadayon, Mehrnaz
Watissee, Marie
Duus, Elizabeth
Dreicer, Robert
机构：
[1] Jimenez Diaz Fdn Univ Hosp, Madrid, Spain
[2] Michigan Inst Urol, Troy, MI USA
[3] In Vivo Sp ZOO, Bydgoszcz, Poland
[4] Urol Ctr Alabama, Homewood, AL USA
[5] Royal Surrey Cty Hosp, Guildford, Surrey, England
[6] Debrecen Oncol, Debrecen, Hungary
[7] Royal Free Hosp, London, England
[8] Hop Foch, Suresnes, France
[9] TMC Pharma, Harley Wintney, England
[10] WStats, London, England
[11] Tavanta Therapeut, King Of Prussia, PA USA
[12] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5052
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial
    von Au, Alexandra
    Milloth, Eva
    Diel, Ingo
    Stefanovic, Stefan
    Hennigs, Andre
    Wallwiener, Markus
    Heil, Joerg
    Golatta, Michael
    Rom, Joachim
    Sohn, Christof
    Schneeweiss, Andreas
    Schuetz, Florian
    Domschke, Christoph
    ONCOTARGETS AND THERAPY, 2016, 9 : 4173 - 4180
  • [32] A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway
    Abu-Khalaf, Maysa
    Mayer, Ingrid
    Litten, Jason B.
    Raponi, Mitch
    Allen, Andrew R.
    Pusztai, Lajos
    Arteaga, Carlos L.
    CANCER RESEARCH, 2015, 75
  • [33] A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer
    McKay, Rana R.
    Werner, Lillian
    Jacobus, Susanna J.
    Jones, Xandra
    Mostaghel, Elahe A.
    Marck, Brett T.
    Choudhury, Atish D.
    Pomerantz, Mark M.
    Sweeney, Christopher J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    CANCER, 2019, 125 (04) : 524 - 532
  • [34] S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer A Randomized, Open-Label Phase 2 Trial
    Du, Feng
    Zheng, Zhaoxu
    Shi, SuSheng
    Jiang, Zhichao
    Qu, Tao
    Yuan, Xinhua
    Sun, Yongkun
    Song, Yan
    Yang, Lin
    Zhao, Jiuda
    Wang, Jinwan
    Chi, Yihebali
    MEDICINE, 2015, 94 (23) : e958
  • [35] Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial (vol 15, pg 1263, 2014)
    Sternberg, C. N.
    Castellano, D.
    Daugaard, G.
    LANCET ONCOLOGY, 2014, 15 (12): : E528 - E528
  • [36] Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate
    Loriot, Y.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 694 - 695
  • [37] ADT/Abiraterone Acetate/Prednisolone for Patients with non-metastatic Prostate Cancer
    Di Lellis, Maddalena Angela
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (15) : 955 - 956
  • [38] Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate
    Kessler, E. R.
    Gao, D.
    Flaig, T. W.
    Breaker, K.
    Wold, M.
    Wacker, M.
    Lam, E. T.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 668 - 668
  • [39] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [40] Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
    Javier Cortes
    Stacie Hudgens
    Chris Twelves
    Edith A. Perez
    Ahmad Awada
    Louise Yelle
    Susan McCutcheon
    Peter A. Kaufman
    Anna Forsythe
    Galina Velikova
    Breast Cancer Research and Treatment, 2015, 154 : 509 - 520
12345